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Left ventricular hypertrophy (LVH) is an abnormal
increase in left ventricular mass. which is a marker for
and contributes to coronary events, stroke, heart failure,
peripheral arterial disease, and cardiovascular mortality
in patients with hypertension (1-12). LVH is commonly
measured by electrocardiography, echocardiography,
and magnetic resonance imaging Concentric LVH is
an increased left ventricular mass index with a relative
wall thickness ≥0.45 (1). Eccentric LVH is an increased
left ventricular mass index with a relative wall thickness
<0.45 (1). Concentric left ventricular remodeling is a
relative wall thickness ≥0.45 with a normal left ventricular
mass index. Factors influencing left ventricular geometry
in persons with hypertension include: (I) the severity,
duration, and rapidity of onset of the increased pressure
load; (II) the volume load; (III) age, race/ethnicity, and
sex; (IV) comorbidities such as coronary artery disease,
diabetes mellitus, obesity, and valvular heart disease;
(V) the neurohormonal milieu; (VI) alterations of the
extracellular matrix; and (VII) genetic factors (13). Blacks
with hypertension are more likely than whites with
hypertension to develop concentric LVH (13). Women with
hypertension are more likely than men with hypertension
to develop concentric LVH (13). Increasing age in patients
with hypertension is associated with concentric LVH (13).
Diabetes mellitus in patients with hypertension is associated
with concentric LVH, whereas obesity, which is a volume
overload state, and coronary artery disease in patients with
hypertension are more likely to be associated with eccentric
LVH (13).
The electrocardiogram is less sensitive than the
echocardiogram or magnetic resonance imaging in
diagnosing LVH. In a blinded prospective study of 476
patients aged 62 years and older, echocardiographic LVH
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was 67% to 71% present in 167 patients (35%) (14). The
sensitivity of 5 different electrocardiographic criteria in
diagnosing LVH varied from 12% to 29%, the specificity
from 93% to 96%, the positive predictive value from 62%
to 71%, and the negative predictive value from 67% to
71% (14). The Cornell criteria (15) had the highest
sensitivity (29%) in predicting LVH, a specificity of 93%, a
positive predictive value of 69%, and a negative predictive
value of 71% (14).
In a prospective study of 84 blacks and 326 whites older
than 62 years with hypertension, echocardiographic LVH
was present in 71% of blacks and in 56% of whites (1).
Electrocardiographic LVH was present in 20% of blacks
and in 15% of whites (1). Concentric LVH was present
in 60% of blacks and in 40% of whites (1). Eccentric
LVH was present in 12% of blacks and in 17% of
whites (1). At 37-month follow-up of blacks,
echocardiographic LVH increased the incidence of new
coronary events 3.33 times, new stroke 2.76 times, and
new congestive heart failure 3.69 times (1). At 43-month
follow-up of whites, echocardiographic LVH increased
the incidence of new coronary events 2.72 times, new
stroke 2.76 times, and new congestive heart failure
3.69 times (1). At 37-month follow-up of blacks,
electrocardiographic LVH increased the incidence of new
coronary events 1.49 times, new stroke 1.79 times, and
new congestive heart failure 1.31 times (1). At 43-month
follow-up of whites, electrocardiographic LVH increased
the incidence of new coronary events 1.41 times, new stroke
1.94 times, and new congestive heart failure 1.58 times (1).
In elderly blacks, compared with eccentric LVH, concentric
LVH increased the incidence of new coronary events
1.48 times, new stroke 1.2 times, and new congestive heart
failure 1.73 times (1). In elderly whites, compared with
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eccentric LVH, concentric LVH increased the incidence
of new coronary events 1.42 times, new congestive heart
failure 1.82 times, and had a similar incidence of new
stroke (1). Echocardiographic LVH (odds ratio 3.21)
and concentric LVH (odds ratio =2.63) were significant
independent variables for new coronary events in the final
multiple logistic regression model for all patients with
hypertension (1). Echocardiographic LVH (odds ratio 4.17)
and electrocardiographic LVH (odds ratio =2.10) were
significant independent variables for new stroke in the
final multiple logistic regression model for all patients with
hypertension (1). Echocardiographic LVH (odds ratio 2.57)
and concentric LVH (odds ratio =2.44) were significant
independent variables for new coronary events in the final
multiple logistic regression model for all patients with
hypertension (1).
At 4-year follow-up of 406 men, mean age 68 years,
and 735 women, mean age 69 years, in the Framingham
Heart Study, echocardiographic LVH increased the risk of
new coronary events 1.67 times for men and 1.60 times for
women per 50 grams/meter increase in left ventricular mass/
height (3). Echocardiographic LVH was 15.3 times more
sensitive in predicting new coronary events in older men
and 4.3 times more sensitive in predicting new coronary
events in older women than was electrocardiographic
LVH (3).
At 10.2-year follow-up of 253 patients with hypertension,
echocardiographic LVH increased the incidence of
cardiovascular events 2.17 times, cardiovascular death
28 times, and all-cause mortality 8 times (4). Patients with
concentric LVH had the highest incidence of cardiovascular
events and of mortality. Electrocardiographic LVH did
not predict risk (4). At 37-month follow-up of 360 elderly
patients with hypertension or coronary artery disease,
echocardiographic LVH increased the incidence of new
coronary events 2.0 times and of new stroke 2.8 times (6).
Electrocardiographic LVH increased the incidence of new
coronary events 1.4 times and of new stroke 1.7 times (6).
Echocardiographic LVH was 4.3 times more sensitive in
predicting new coronary events and 4.0 times more sensitive
in predicting new stroke than was electrocardiographic
LVH (6).
At 4-year follow-up of 3,220 persons aged 40 years and
older in the Framingham Heart Study, echocardiographic
LV H i n c r e a s e d t h e r i s k o f c a r d i o v a s c u l a r e v e n t s
1.49 times for men and 1.57 times for women per
50 grams/meter increase in left ventricular mass/height,
the risk of cardiovascular death 1.73 times for men and
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2.12 times for women per 50 grams/meter increase in left
ventricular mass/height, and the risk of all-cause mortality
1.49 times for men and 2.01 times for women per 50 grams/
meter increase in left ventricular mass/height (7). At 6- to
7-year follow-up of 5,888 persons, mean age 73 years, in
the Cardiovascular Health Study, compared to the lowest
quartile of echocardiographic left ventricular mass, the
highest quartile of echocardiographic left ventricular mass
increased the incidence of coronary events 1.43 times,
the incidence of stroke 1.52 times, and the incidence of
congestive heart failure 3.36 times (8). Compared with
normal left ventricular geometry, eccentric LVH increased
the incidence of coronary events 2.05 times and for
congestive heart failure 2.95 times. Compared with normal
left ventricular geometry, concentric LVH increased the
incidence of coronary events 1.61 times and for congestive
heart failure 3.32 times (8).
At 42-month follow-up of 2,638 persons, mean age
81 years, the incidence of new congestive heart failure
was increased 2.73 times in persons with persistent
electrocardiographic LVH compared with persons without
electrocardiographic LVH (9). At 4.8-year follow-up
of 922 patients with hypertension, patients with both
echocardiographic LVH and electrocardiographic LVH had
a 5.3 times higher incidence of hospitalization for congestive
heart failure than patients without electrocardiographic
or echocardiographic LVH (10). Patients with both
echocardiographic LVH and electrocardiographic LVH had
a 2.6 times higher incidence of hospitalization for congestive
heart failure than patients without electrocardiographic
LVH who had echocardiographic LVH (10).
At 10-year follow-up of 2,577 community-dwelling
adults, mean age 72 years, in the Cardiovascular
Health study, addition of a 1-standard deviation higher
echocardiographic left ventricular mass index to the 10-year
risk prediction models containing traditional risk factors
improved risk prediction for incident coronary heart disease
25%, for incident coronary heart disease or heart failure
or stroke 24%, and for incident congestive heart failure
51% (11). The Multi-Ethnic Study of Atherosclerosis
(MESA) Study performed cardiac magnetic resonance
imaging for measurement of left ventricular mass and
geometry to predict incident cardiovascular events in 5,098
persons aged 45 to 84 years old (12). At 4-year follow-up,
concentric LVH increased the incidence of coronary heart
disease 2.1 times per gram/mL of left ventricular mass
to volume ratio and the incidence of stroke 4.2 times per
gram/mL of left ventricular mass to volume ratio (12). Left
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ventricular mass alone increased the incidence of congestive
heart failure 1.4 times per 10% increase in left ventricular
mass (12). There are no data comparing the prognostic
value of left ventricular mass and geometry obtained by
magnetic resonance imaging versus by echocardiography.
At 2.71-year follow-up of 694 persons, mean age
50 years, with hypertension, echocardiographic concentric
left ventricular remodeling increased cardiovascular events
2.56 times compared with echocardiographic normal
left ventricular geometry (16). Echocardiograms were
obtained in 9,771 patients older than 70 years with a normal
left ventricular ejection fraction who were followed for
3.1 years (17). All-cause mortality was 15.9% in patients
with concentric LVH, 15.5% in patients with concentric left
ventricular remodeling, 13.7% in patients with eccentric
LVH, and 11.5% in patients with normal left ventricular
geometry (17).
A prospective cohort sub-study of 941 patients aged 55
to 80 years old in the Losartan Intervention for Endpoint
Reduction in Hypertension (LIFE) trial with hypertension
and electrocardiographic LVH had left ventricular mass
measured by echocardiography (18). At 4.8-year followup, reduction in echocardiographic left ventricular mass
index by antihypertensive drug treatment reduced the
incidence of cardiovascular mortality by 38%, stroke
by 24%, myocardial infarction by 15%, and all-cause
mortality by 28%, independent of systolic blood pressure
and assigned treatment (18). At 4-year follow-up of 9,193
persons aged 55 to 80 years old with hypertension and
electrocardiographic LVH diagnosed by Cornell criteria
or by Sokolow-Lyon voltage criteria in the LIFE trial,
less severe electrocardiographic LVH by the Cornell
criteria and by the Sokolow-Lyon voltage criteria were
associated with a 14% and 17%, respectively, decrease in
the composite endpoint of cardiovascular death, myocardial
infarction, or stroke (19). At 4.7-year follow-up of 8,479
persons, mean age 67 years old, with hypertension and
electrocardiographic LVH diagnosed by the Cornell criteria,
less severe electrocardiographic LVH was associated with
a 19% reduction in heart failure hospitalization for every
817-mm·msec lower Cornell product (20). In an outpatient
clinic, at 67-month follow-up of patients with hypertension
and echocardiographic LVH, regression of LVH occurred
in 23% of patients treated with antihypertensive drugs (21).
A meta-analysis was performed of 5 studies
including 3,149 patients, mean age range 48 to
66 years old, with hypertension investigating the effect of
regression of echocardiographic LVH on cardiovascular
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events (22). Follow-up ranged from 3 to 9 years. Regression
of echocardiographic LVH was associated with a 46%
reduction in cardiovascular events (22).
Loss of weight and reduction of sodium intake in
patients with hypertension are effective in reducing
echocardiographic LVH (23). Aggressive blood pressure
control should be used to cause regression of LVH (21).
A meta-analysis of 109 treatment studies including 2,357
patents with hypertension showed that angiotensinconverting enzyme inhibitors were the most effective
antihypertensive drugs in reducing left ventricular mass (24).
This analysis showed that angiotensin-converting enzyme
inhibitors, beta blockers, and calcium channel blockers
reduced left ventricular mass by reducing wall thickness,
whereas diuretics reduced left ventricular mass by reducing
left ventricular volume (24). Alpha-adrenergic blockers (25)
and direct-acting vasodilators (26) did not reduce left
ventricular mass.
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